These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24261610)

  • 1. Novel investigational agents for the treatment of scleroderma.
    McMahan ZH; Wigley FM
    Expert Opin Investig Drugs; 2014 Feb; 23(2):183-98. PubMed ID: 24261610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
    McMahan ZH; Volkmann ER
    Expert Opin Pharmacother; 2020 Nov; 21(16):2041-2056. PubMed ID: 32674612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
    Hasegawa M; Takehara K
    Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cells in systemic sclerosis: a possible target for therapy.
    Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
    Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis.
    Hasegawa M
    J Dermatol; 2010 Jan; 37(1):3-10. PubMed ID: 20175836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic sclerosis: an update.
    Varga J
    Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs in phase I and phase II clinical trials for systemic sclerosis.
    Chung MP; Chung L
    Expert Opin Investig Drugs; 2020 Apr; 29(4):349-362. PubMed ID: 32178544
    [No Abstract]   [Full Text] [Related]  

  • 10. Investigational drugs for the treatment of scleroderma: what's new?
    Colic J; Campochiaro C; Hughes M; Matucci Cerinic M; Dagna L
    Expert Opin Investig Drugs; 2023; 32(7):601-614. PubMed ID: 37526079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
    Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP
    Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current options for the treatment of systemic scleroderma.
    McGee BA; Barnett MD; Small RE
    Clin Pharm; 1991 Jan; 10(1):14-25. PubMed ID: 1999084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in the pathogenesis of systemic sclerosis.
    Sakkas LI
    Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
    Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
    Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of biologics and other novel therapies for the treatment of systemic sclerosis.
    Bruni C; Praino E; Allanore Y; Distler O; Gabrielli A; Iannone F; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2017 May; 13(5):469-482. PubMed ID: 27899043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel insights on the role of the innate immune system in systemic sclerosis.
    York MR
    Expert Rev Clin Immunol; 2011 Jul; 7(4):481-9. PubMed ID: 21790291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis.
    Badea I; Taylor M; Rosenberg A; Foldvari M
    Rheumatology (Oxford); 2009 Mar; 48(3):213-21. PubMed ID: 19022832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of systemic sclerosis.
    Postlethwaite AE; Harris LJ; Raza SH; Kodura S; Akhigbe T
    Expert Opin Pharmacother; 2010 Apr; 11(5):789-806. PubMed ID: 20210685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.